Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
about
Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerCirculating Tumor Cell and Cell-free Circulating Tumor DNA in Lung CancerCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancerMeta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significanceOsimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyMutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platformPredicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.Superior Multiplexing Capacity of PlexPrimers Enables Sensitive and Specific Detection of SNPs and Clustered Mutations in qPCRTumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.Circulating tumor DNA detection in lung cancer patients before and after surgeryMutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patientsA Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistanceContribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.EGFR mutations in lung cancer: from tissue testing to liquid biopsy.AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trialsA case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer.Molecular pathology in real time.Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.The liquid biopsy in lung cancerLiquid biopsies come of age: towards implementation of circulating tumour DNA.Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patientsDynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment.Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patientsMonitoring cancer through the blood.Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.
P2860
Q26741814-ADC999D3-69AD-4F8B-BD8E-E9D3C1E5B199Q26775376-8636A633-A94F-4454-ABBF-FF07761C417AQ28067582-CAE05085-7FC2-4F9D-997D-C8A470FACF57Q28077340-214D8857-C99E-46F6-898C-7E16266D8AF9Q28079253-D59F1E58-2D08-4249-AB09-B73181F6C758Q33621143-4129BFE1-8828-4DD7-9EB3-365AE0857E73Q33751216-A93E45EE-914C-41D0-8FD6-18266C0042A6Q33757134-9B9E471D-95B8-4897-89E8-3B326BEA8C7CQ34457501-226B1FFA-E98E-45E6-BB48-345A33CF8BCEQ36073981-744163D3-E9A1-44E2-86B7-9484216F852EQ36257385-F52815FA-C3D7-4996-869E-5F2B835955EAQ36318892-C176BEEA-E586-4124-B62D-8C9B3D87C464Q36544438-E815CA5C-93F0-4AEE-85ED-D97102666B13Q36574146-9C9705A9-4733-4901-85D5-C3310BC374E2Q36643142-BE0EB198-C520-4511-8647-1818D9FD17EBQ36916399-CFD272A9-E616-4F4C-9E7D-086C6D8A44A0Q37000646-E03ABAE3-38D1-4393-BD4B-0317BCBA88E9Q37190448-7B0ADC6C-4B38-4657-B04D-1A0D1B8B551CQ37264643-3660D0F0-D698-4909-9762-B8FC3144C3F1Q37264652-0C6968B9-514A-4C09-97C1-CB8E25FF1209Q37609221-617ECDDD-1F30-4F05-9A86-4B1D0ED15FC4Q37706672-757785C4-CA84-4249-8CE4-51CEEF816925Q37723666-16660B1F-23BF-4DAB-B9ED-ADA0CC628EA2Q38515822-E3372F1C-1392-456B-8962-455332FFF8F0Q38549733-394CFC3E-4034-4686-82EC-1D2A2BAB0EC0Q38671947-5FE4470E-292D-41FE-ACE1-FFC8F85AAED8Q38694431-F923254C-AC78-49E0-921D-65569C479CACQ38701620-DDB2C882-5A33-42BD-B76A-015CDE88982BQ38756841-A3C2E31F-DE36-41BC-BD2E-D4BA450A44E3Q38772190-91646F46-81B9-470A-AF5E-44C78A6081DCQ38844281-BC4C0B62-AC8D-4EB8-9493-A3728583E251Q38845760-F2A33653-6843-4FA8-B802-345DE1998CA7Q39132753-13038B1A-F186-4696-801A-D6DD381113A7Q39149201-376E7142-D575-40DB-B0E0-80FDB82D89A1Q41260159-10378E6D-21FF-406A-9353-40731D73D80AQ41524917-D6FA395F-7F6A-4B58-B8D9-57DDA3A97C21Q41694055-21424429-BF3F-465C-A42D-B9A6AE427A8CQ42362771-4063CA5B-2764-4B20-BA72-F7348B5FCBAEQ42953876-082DFA6B-6FE1-4988-BD70-2EC38FCA0B3BQ46328392-A36E0443-228B-4164-A90D-89FEB3B28115
P2860
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Monitoring of epidermal growth ...... ring treatment with erlotinib.
@ast
Monitoring of epidermal growth ...... ring treatment with erlotinib.
@en
type
label
Monitoring of epidermal growth ...... ring treatment with erlotinib.
@ast
Monitoring of epidermal growth ...... ring treatment with erlotinib.
@en
prefLabel
Monitoring of epidermal growth ...... ring treatment with erlotinib.
@ast
Monitoring of epidermal growth ...... ring treatment with erlotinib.
@en
P2093
P2860
P50
P356
P1433
P1476
Monitoring of epidermal growth ...... ring treatment with erlotinib.
@en
P2093
P2860
P304
P356
10.1002/CNCR.28964
P407
P577
2014-08-07T00:00:00Z